CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Rituximab +12 morebiological
Likely dose
Rituximab 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02260934
NCT02260934Phase 2Completed

Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Oct 9, 2014·Updated Dec 1, 2020

In Brief

A Phase 2 clinical trial evaluating Rituximab, Cyclophosphamide, and 5 other interventions for Lupus Nephritis. Completed, enrolled 43 participants across 15 sites.

Detailed Summary

In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Nephritis
CountriesUnited States

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 9, 2014
Enrollment StartJul 9, 2015
Primary CompletionMar 12, 2018
Study CompletionFeb 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.7 years ago

Interventions

Rituximabbiological

Rituximab 1000mg intravenously (IV) at week 0 and week 2

Cyclophosphamidedrug

Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.

Prednisonedrug

* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12) * Continue prednisone 10 mg/day to week 96

Methylprednisolonedrug

Week 0 and Week 2: Solumedrol (100 mg) IV

Diphenhydraminedrug

Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

Acetaminophendrug

Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

Rituximabbiological

Rituximab 1000mg intravenously (IV) at week 0 and week 2.

Cyclophosphamidedrug

Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.

Prednisonedrug

* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12) * Continue prednisone 10 mg/day to week 96

Methylprednisolonedrug

Week 0 and Week 2: Solumedrol (100 mg) IV

Diphenhydraminedrug

Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

Acetaminophendrug

Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

Belimumabbiological

The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48